Herantis Pharma Oyj reported unaudited consolidated earnings results for the six months ended June 30, 2016. For the period, the company reported net turnover of EUR 25,291.91 against EUR 1,155.00 a year ago. Operating loss was EUR 2,572,868.67 against EUR 13,730,577.13 a year ago. Loss before extraordinary items was EUR 2,597,483.33 against EUR 13,585,199.11 a year ago. Loss before appropriations and taxes was EUR 2,597,483.33 against EUR 13,585,199.11 a year ago. Consolidated loss was EUR 2,597,483.33 against EUR 13,585,199.11 a year ago. Cash flow used in operating activities was EUR 2,113,037.51 against EUR 5,335,813.11 a year ago. Investments on tangible and intangible assets were EUR 6,588.61. Loss per share was EUR 0.63 compared with EUR 3.34 a year ago.

The company does not expect essential revenue in 2016.